Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Substituted phenethylaminecocaine, amphetamine, methamphetamine +2 morecocaine, amphetamine, methamphetamine, MDPV, methylphenidate show less
A-PVP
α-pyrrolidinopentiophenone
α-PVP (α-pyrrolidinopentiophenone) — also known as Flakka — is a synthetic stimulant of the cathinone class. It is a close structural relative of MDPV, with even greater dopamine selectivity.[1][2] It blocks dopamine and norepinephrine recycling in the brain,[3] flooding reward circuits with dopamine and driving intense stimulation.
α-PVP (α-pyrrolidinopentiophenone) — also known as Flakka — is a synthetic stimulant of the cathinone class. It is a close structural relative of MDPV, with even greater dopamine selectivity.[1][2] α-PVP is a dopamine and norepinephrine reuptake inhibitor, producing its effects by blocking dopamine clearance from the synapse without triggering monoamine release.[3]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Substituted phenethylaminecocaine, amphetamine, methamphetamine +2 morecocaine, amphetamine, methamphetamine, MDPV, methylphenidate show less
α-PVP emerged around 2011 as a direct replacement for MDPV and other bath salt cathinones that had just been banned.[2] It gained international attention during the 2014–2015 Flakka epidemic in Florida, when erratic, violent, and delusional public behavior drew intense media coverage. Despite permanent scheduling in the US in 2017 and EU-wide control in 2016, α-PVP remains prevalent in forensic casework across Europe.[4]
Subjective effects include euphoria, sharp focus, increased energy, and a compulsive compulsive redosing urge. The experience is narrowly dopaminergic — driven reward and motivation without the warmth of serotonin-active drugs like mephedrone.[5] Paranoia, hallucinations, aggression, and cardiovascular strain are characteristic unsought effects, especially after repeated use.
α-PVP produces rapid psychological dependence and carries high risk of cardiovascular emergency, psychosis, and muscle breakdown.[6] Compulsive redosing is the central danger — extreme dopamine selectivity creates a relentless drive to use again, and each additional dose raises the risk of acute psychosis, heart crisis, and kidney injury.[2][4] The evidence base is largely preclinical; the first controlled human pharmacokinetic data were not published until 2025.[7]
History[edit]
Discovery
α-PVP is a structural analog of pyrovalerone, a clinical anti-fatigue compound developed in the 1960s.[5][8] The exact date and laboratory of first synthesis have not been confirmed, though the compound likely dates to early pyrovalerone analog patent work from that era.[8]
Emergence and the "Flakka" epidemic
α-PVP was identified by European drug monitoring authorities in 2011[9] and appeared in US clinical specimens the same year.[10] It spread as a direct replacement for MDPV and other newly banned bath salt cathinones.[2][11] It gained international notoriety in 2014–2015 when erratic, violent, and delusional incidents in Broward County, Florida drew intense media coverage.[5][8]
Scheduling and modern prevalence
The US DEA placed α-PVP under Schedule I in 2014, with permanent placement in 2017.[12] EU-wide controls followed by Council Decision in 2016.[9] α-PVP remains prevalent in European forensic casework, and its scaffold continues to generate next-generation designer cathinones.[13][4][14]
The street name "Flakka" — sometimes also "Gravel" — became synonymous with α-PVP during the 2014–2015 media cycle covering bizarre behavioral incidents in South Florida. Concurrently, reports of traffic accidents caused by α-PVP-impaired drivers in Japan prompted domestic regulatory action.[15]
Chemistry[edit]
Structural class
α-PVP belongs to the pyrrolidinophenone subclass of synthetic cathinones — the same structural family as MDPV and pyrovalerone.[8][5] Its molecular formula is C₁₅H₂₁NO (molecular weight 231.33 g/mol).
It differs from MDPV by the absence of a methylenedioxy group on the phenyl ring, and from pyrovalerone by the absence of one methyl group.[3]
Pharmacology[edit]
Mechanism of action
α-PVP blocks the proteins that normally recycle dopamine and norepinephrine out of the brain's signaling gaps.[1] Unlike amphetamines, it does not force their release — it amplifies signals already being sent.[3][16] Its selectivity for dopamine over serotonin far exceeds cocaine's, producing intense reward-and-drive stimulation without serotonin's warmth.[1][2]
Pharmacokinetics
Human pharmacokinetic data come from a single observational study of intranasal use.[7] After snorting 10 or 20 mg, peak drug levels in oral fluid were reached at 47–60 minutes — notably later than related cathinones, possibly reflecting the pyrrolidine ring's effect on absorption.[7]
Metabolism
The body primarily breaks α-PVP down by opening its pyrrolidine ring, producing degradation products detectable in urine.[7][10] Bioavailability, protein binding, and half-life have not been characterized by any route.
Neuroscience[edit]
Where it acts
α-PVP floods the brain's main reward region — the nucleus accumbens — with dopamine immediately after use.[15][16] This surge drives the intense craving and compulsive urge to use again that define the α-PVP experience.
Why it matters
α-PVP activates the brain's wanting system more than its pleasure system — the dopamine surge creates craving and motivation rather than sustained satisfaction. The result is relentless redosing despite diminishing euphoria.
Chronic high-dose use damages the brain directly. Memory and spatial learning are impaired through energy failure inside brain cells,[17] and repeated use produces brain inflammation with sex-dependent patterns — males develop widespread brain inflammation, while females show predominantly peripheral inflammatory changes.[18]
The dose threshold for cognitive damage in humans is unknown — animal data show a clear effect, but translation to human use patterns has not been studied.[17] In animals, females show greater locomotor sensitivity[19][20][21] and different inflammatory patterns[18] compared to males, but whether this translates to differential human risk is unknown. Whether brain changes reverse with cessation has not been studied.
Subjective Effects[edit]
The α-PVP experience is narrow and driven — a surge of motivation, focus, and reward without the social warmth or perceptual richness of other stimulants. Compulsive redosing is not incidental but pharmacological: the dopamine surge creates relentless wanting, and each dose renews the urge to use again.
Compared to cocaine, α-PVP produces qualitatively similar but more potent dopaminergic stimulation — rhesus monkeys cannot distinguish the two in behavioral tests.[22] Against its closest relative MDPV, α-PVP achieves even greater dopamine selectivity[2] and a comparable compulsive-use profile.
α-PVP appeared on the EMCDDA early warning system in 2011 as a replacement for recently scheduled cathinones including MDPV and mephedrone.[2] It gained international notoriety during the 2014–2015 "Flakka" epidemic in Florida, driving emergency scheduling in the United States and European Union. Despite widespread control, α-PVP remains prevalent in forensic casework — it was detected in 118 post-mortem cases in Finland between 2018 and 2023.[4]
Subjective effects include euphoria, psychomotor activation, increased focus, and heightened wakefulness. The experience is intensely dopaminergic — a narrow, driven stimulation without the empathogenic warmth of serotonin-active cathinones,[5] producing a compulsive compulsive redosing urge that defines the use pattern. Paranoia, psychosis, aggressive behavior, and severe cardiovascular strain are characteristic unsought effects.
α-PVP produces among the highest reinforcing potency of any cathinone tested,[2] with psychological dependence developing rapidly; no lethal dose has been established, and nearly all fatalities involve polydrug use.[4] Compulsive redosing is the central risk — extreme dopamine selectivity drives relentless motivation to use again, while escalating doses bring psychosis, muscle breakdown,[6] and cardiovascular emergency. The evidence base is preclinical-dominant, with the first controlled human pharmacokinetic data not published until 2025[7] and no clinical trials conducted.
History[edit]
Discovery
α-PVP is a structural analog of pyrovalerone, a compound developed in the 1960s as a clinical anti-fatigue agent, differing only by the removal of one methyl group from the phenyl ring.[5][8] The exact date and laboratory of first synthesis have not been confirmed, though the compound likely appears in early pyrovalerone analog patent series from that era.[8] α-PVP constitutes one of two principal chemical scaffolds for the synthetic cathinone designer drug family, the other being the methcathinone scaffold.[3]
Emergence and the "Flakka" epidemic
α-PVP was first identified by the EMCDDA early warning system in 2011[9] and appeared in US clinical specimens as early as February of that year.[10] The compound emerged as a direct structural replacement following emergency scheduling of MDPV, mephedrone, and methylone — the "first-generation" bath salt compounds — and was classified as a "second-generation" synthetic cathinone.[2][11] It attracted intense media attention in 2014–2015, particularly in Broward County, Florida, where erratic public behavior, violence, and excited delirium were attributed to its use.[5][8]
Scheduling and modern prevalence
The US DEA placed α-PVP under temporary Schedule I control in February 2014, with permanent placement following in March 2017.[12] The EMCDDA completed its risk assessment in November 2015, leading to EU-wide control measures enacted by Council Decision in June 2016.[9] Following scheduling, α-PVP's structural scaffold became the basis for next-generation designer cathinones — halogenated and alkyl-modified analogs that continued to appear on drug markets[13] — while α-PVP itself remains prevalent in forensic casework across Europe.[4][14]
The street name "Flakka" — sometimes also "Gravel" — became synonymous with α-PVP during the 2014–2015 media cycle covering bizarre behavioral incidents in South Florida. The term's etymology is unclear but was rapidly adopted by US media. Concurrently, reports of traffic accidents caused by α-PVP-impaired drivers in Japan prompted domestic regulatory action.[15]
Chemistry[edit]
Structural class
α-PVP belongs to the pyrrolidinophenone (pyrovalerone) subclass of synthetic cathinones. The molecule combines a phenethylamine backbone with a β-keto group and an α-pyrrolidine ring — the defining features of this subclass.[8] It is structurally related to pyrovalerone and MDPV, differing from pyrovalerone by the absence of a methyl group on the phenyl ring and from MDPV by the absence of the methylenedioxy group.[5][3]
Molecular properties
| Molecular formula | C₁₅H₂₁NO |
| Molecular weight | 231.33 g/mol |
The molecule consists of a phenyl ring connected to a pentanone chain bearing a pyrrolidine nitrogen at the α-carbon. The five-carbon chain (including the carbonyl carbon) distinguishes α-PVP from shorter-chain relatives such as α-PPP (propyl) and α-PBP (butyl). Structure-activity studies confirm that the pyrrolidine ring and extended alkyl chain together confer the highest potency at dopamine and norepinephrine transporters — chain length and pyrrolidine bulk are the principal determinants of transporter binding.[5][16]
Stereochemistry
α-PVP has one chirality center and is sold as a racemic mixture. The S-enantiomer is the pharmacologically active form, 10–20× more potent than the R-enantiomer at dopamine and norepinephrine transporters.[17] All significant neurochemical, behavioral, and cardiovascular effects of the racemate are driven by the S-isomer.[17]
Physical properties
α-PVP is typically encountered as a white or off-white crystalline powder in its hydrochloride salt form.[8] No published characterization of melting point, solubility, or stability has been identified, and degradation pathways under storage conditions have not been systematically studied. citation needed
Pharmacology[edit]
Mechanism of action
α-PVP blocks the DAT (DAT) and NET (NET) with extreme selectivity, while having negligible activity at the SERT.[1] Unlike amphetamine-type cathinones such as mephedrone and methcathinone, α-PVP is a pure transporter blocker — it prevents dopamine and norepinephrine from being cleared from the synapse but does not force their release.[3][18]
This distinction matters. Release-type stimulants flood the synapse with monoamines regardless of neural activity, while reuptake inhibitors amplify signals already being sent. The result is an experience driven almost entirely by dopamine — reward, motivation, and motor drive — without the serotonin-mediated warmth or empathy seen with drugs like MDMA. For comparison, cocaine's DAT/serotonin transporter ratio is approximately 1.64; α-PVP's exceeds 4,030.[1][2]
At higher concentrations in laboratory assays, α-PVP produces partially irreversible inhibition of neuronal activity.[16] None of 11 tested analogs significantly inhibited serotonin uptake even at high concentrations.[5]
Pharmacokinetics
Human pharmacokinetic data are limited to a single observational study of intranasal administration.[7] No controlled studies exist for oral, smoked, or intravenous routes.
In that study, eight volunteers self-administered 10 mg or 20 mg intranasally. Peak concentrations in oral fluid were reached at 47–60 minutes post-dose — notably later than non-pyrrolidine synthetic cathinones, possibly reflecting how the pyrrolidine ring affects absorption or distribution.[7]
Metabolism
Ten metabolites were identified following intranasal dosing. The primary pathway involves opening of the pyrrolidine ring, producing an N-butanoic acid metabolite as the most abundant urinary species.[7] Earlier analysis of US urine specimens confirmed excretion of unchanged α-PVP alongside ring degradation products.[10]
The specific liver enzymes responsible for α-PVP metabolism have not been identified in humans. Bioavailability, distribution volume, protein binding, and half-life remain uncharacterized by any route.
Neuroscience[edit]
Where it acts
α-PVP's primary neural action is amplification of dopamine signaling in the brain's mesolimbic reward circuit. Administration increases dopamine levels in the nucleus accumbens — the region most associated with motivation and reward — immediately following dosing.[15][18] This drives the intense craving and compulsive redosing that define the α-PVP experience.
Repeated administration shifts the neurochemical picture. In animal models, chronic self-administration increased norepinephrine and glutamate in the hypothalamus with minimal lasting dopamine changes, suggesting long-term use shifts the dominant brain impact from dopamine toward stress and excitatory systems.[19]
Why it matters
α-PVP's extreme dopamine selectivity positions it as a prototypical "wanting" compound within the incentive salience framework — the dopamine-dominant mechanism preferentially drives motivational craving over hedonic pleasure. This predicts high compulsive-use potential with diminishing satisfaction, consistent with reports of relentless redosing despite declining euphoria.
Chronic use also damages the brain directly. Repeated high-dose administration impairs spatial learning and memory through mitochondrial dysfunction — increased oxidative stress and energy failure in brain cells.[20] Extended self-administration produces neuroinflammation with sex-dependent patterns: males develop widespread brain inflammation, while females show predominantly peripheral inflammatory responses.[21]
The dose threshold at which mitochondrial-mediated cognitive damage emerges in humans is unknown — animal data show a clear threshold effect, but translation to human use patterns has not been studied.[20] Sex differences in vulnerability are pronounced in animals — females show greater locomotor sensitivity[22][23][24] and different neuroinflammatory patterns[21] — but whether this translates to differential human risk is unknown.
Subjective Effects[edit]
The α-PVP experience is dominated by its extreme dopamine selectivity. The stimulation is narrow and driven — motivation, focus, and reward are amplified without the empathogenic or entactogenic warmth seen with serotonin-releasing cathinones like mephedrone. Route of administration shapes the experience dramatically: smoked α-PVP delivers a brief, intense rush that powerfully drives compulsive redosing, while insufflated administration produces a longer, more manageable arc. At higher doses, pharmacological compulsion overrides set and setting, and paranoia can emerge regardless of environment.
Relative to cocaine, α-PVP produces qualitatively similar but more potent dopaminergic stimulation — rhesus monkeys cannot distinguish the two in discrimination assays.[25] Compared to MDPV, its closest structural relative, α-PVP achieves even greater dopamine selectivity[2] with a comparable compulsive-use profile.
Effect Grid
At common doses, the full stimulant experience manifests: pronounced euphoria, strong psychomotor activation, thought acceleration, and marked sociability. Confidence and motivation increase substantially. Time distortion (compression) is typical, with hours passing subjectively faster.
Cardiovascular effects become significant — tachycardia, elevated blood pressure, and peripheral vasoconstriction. Appetite suppression is complete. Bruxism and jaw clenching are common. Diaphoresis (sweating) may occur. Body temperature begins to rise.
Compulsive redosing becomes a prominent feature at this tier, particularly via smoked and insufflated routes. Sleep is impossible for 3-6 hours. Functional impairment increases with repeated dosing within a session.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Touch enhancement · Peripheral misidentification · Auditory distortion · Music enhancement · Auditory misinterpretation · Spatial disorientation · Visual acuity enhancement · Visual processing acceleration · Dreaming enhancement · Visual haze / noise · Brightness alteration · Visual drifting · Visual acuity suppression · Color enhancement · Peripheral vision distortion · Perspective distortion · Proprioceptive distortion · Tinnitus · Vestibular distortion · Touch suppression · Auditory hallucinations · External hallucinations · Persisting hallucinations · Shadow people
Auditory misinterpretation · Spatial disorientation · Visual acuity enhancement · Visual processing acceleration · Dreaming enhancement · Visual haze / noise · Brightness alteration · Visual drifting · Visual acuity suppression · Color enhancement · Peripheral vision distortion · Perspective distortion · Proprioceptive distortion · Tinnitus · Vestibular distortion · Touch suppression · Auditory hallucinations · External hallucinations · Persisting hallucinations · Shadow people
Pupil dilation · Restlessness · Insomnia · Physical fatigue · Dry mouth · Excessive sweating · Body high · Heart rate perception changes · Muscle tension · Dehydration sensation · Respiratory stimulation · Tactile euphoria · Temperature dysregulation · Trembling · Spontaneous body sensations · Headache · Bruxism · Sexual arousal enhancement · Involuntary body movements · Breathing alteration · Dizziness · Motor control impairment · Nausea · Tingling / electric sensations · Increased urination · Seizure threshold reduction · Bodily lightness · Nasal congestion · Vibrations / buzzing · Vomiting · Constipation · Tactile hallucination
Physical fatigue · Dry mouth · Excessive sweating · Body high · Heart rate perception changes · Muscle tension · Dehydration sensation · Respiratory stimulation · Tactile euphoria · Trembling · Spontaneous body sensations · Headache · Bruxism · Sexual arousal enhancement · Involuntary body movements · Breathing alteration · Dizziness · Motor control impairment · Nausea · Tingling / electric sensations · Increased urination · Seizure threshold reduction · Bodily lightness · Nasal congestion · Vibrations / buzzing · Vomiting · Constipation · Tactile hallucination
Cognitive dysphoria · Motivation enhancement · Motivation suppression · Immersion enhancement · Focus enhancement · Analysis enhancement · Analysis suppression · Cognitive impairment · Confusion · Information processing enhancement · Multiple thought streams · Novelty enhancement · Thought connectivity · Thought disorganization · Thought loops · Cognitive flexibility · Creativity suppression · Focus suppression · Information processing suppression · Memory fragmentation · Memory suppression · Pattern recognition enhancement · Creativity enhancement · Language enhancement · Memory enhancement · Thought organization · Thought deceleration · Delusions of sobriety · Language suppression · Delusions · Delirium
Immersion enhancement · Focus enhancement · Analysis enhancement · Analysis suppression · Cognitive impairment · Confusion · Information processing enhancement · Multiple thought streams · Novelty enhancement · Thought connectivity · Thought disorganization · Thought loops · Cognitive flexibility · Creativity suppression · Focus suppression · Information processing suppression · Memory fragmentation · Memory suppression · Pattern recognition enhancement · Creativity enhancement · Language enhancement · Memory enhancement · Thought organization · Thought deceleration · Language suppression · Delusions · Delirium
Anhedonia · Dysphoria · Emotional enhancement · Emotional lability · Empathy suppression · Mania
Emotional lability · Empathy suppression
Emotional susceptibility · Sociability suppression · Social disconnection · Communication enhancement · Sociability enhancement · Communication suppression · Flow state · Depersonalization · Derealization · Cognitive disconnection · Identity alteration
Sociability enhancement · Communication suppression · Flow state · Depersonalization · Derealization · Cognitive disconnection · Identity alteration
Timeline
Initial awareness of stimulation within 2-10 minutes of insufflation. Slight nasal burning followed by a building sense of alertness and mild mood shift.
Stimulation intensifies over 10-30 minutes. Euphoria, thought acceleration, and cardiovascular activation build progressively. Heart rate and blood pressure begin rising.
Maximum euphoria, psychomotor activation, and cardiovascular effects at 45-90 minutes. Tmax measured at 47-60 minutes in PK studies. Compulsive redosing urge is strongest during this phase.
Sustained stimulation with gradually declining euphoria over 1-2 hours. Residual cardiovascular activation persists. Anxiety and restlessness may replace euphoria, particularly at higher doses.
Stimulation fades over 1-2 hours. Fatigue, irritability, and dysphoria emerge as dopaminergic effects wane. Appetite begins returning.
Residual fatigue, low mood, and mild cognitive impairment lasting 2-6 hours. Sleep quality may be disrupted even after subjective effects resolve.
⚠ Do not drive or operate machinery until after a full sleep cycle following use.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- rapid
- Tolerance reset
- 10 days
- Physical
- Low
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- cocaine · amphetamine · methamphetamine
Toxicity
Acute toxicity
No lethal dose has been established. The acute toxicity pattern is a cascade of overstimulation: rapid heart rate, high blood pressure, elevated body temperature, seizures, extreme agitation, muscle breakdown, and kidney injury.[23][24]
In 34 Finnish fatal cases from 2018–2023, blood concentrations ranged from 0.03 to 2.6 mg/L.[4] The wide range reflects polydrug involvement rather than an intrinsic lethal threshold — only 1.7% of fatal synthetic cathinone cases involved α-PVP alone, and α-PVP was implicated in the cause of death in 29% of cases where it was detected.[4]
α-PVP is not detected by standard urine drug screens. Confirmation requires specialized laboratory testing.[8][7] Emergency physicians should consider synthetic cathinone exposure in patients presenting with unexplained stimulant toxicity and negative routine screening.
Muscle breakdown
α-PVP damages muscle through two routes. Indirect damage results from overstimulation — elevated body temperature and sustained muscle hyperactivity. Direct damage occurs at the cellular level: α-PVP impairs energy production inside muscle cells, increasing oxidative stress.[6] Muscle breakdown-induced kidney injury is a prominent feature of severe toxicity.[25]
Cognitive toxicity
Repeated high-dose use impaired spatial learning and memory in rats through brain energy failure.[17] Lower doses did not produce these effects. The dose threshold for cognitive damage in humans has not been characterized.
Polydrug fatality context
In 118 Finnish post-mortem cases from 2018–2023, α-PVP was present alongside opioids, stimulants, or sedatives in 69–92% of cases.[4] Mixed synthetic cathinone poisoning dramatically elevates toxicity risk compared to single-substance exposure.[26]
Psychological risks
α-PVP's extreme dopamine selectivity is strongly associated with acute psychosis. Paranoia, hallucinations, aggression, and severe anxiety are documented in clinical case series.[27][8] High dopamine selectivity carries the highest psychosis risk among synthetic cathinones.[27]
Behavioral toxicity extends to loss of control: erratic public behavior, aggression, and impaired driving were documented during the Flakka epidemic and in Japanese traffic accident reports.[8][15] Chronic use produces brain inflammation with sex-dependent patterns.[18]
Tolerance & dependence
α-PVP has among the highest reinforcing potency of any cathinone tested — 100% of rats in self-administration studies acquired the behavior.[2] Its reinforcing effectiveness exceeds that of cocaine.[11]
Tolerance develops through dopaminergic neuroadaptation. Lasting molecular changes after withdrawal are documented in the closely related MDPV.[28] Physical withdrawal has not been characterized in human studies; psychological dependence potential is strongly supported by preclinical data. inferred
Drug Interactions
The interaction profile is poorly characterized, with no substance-specific combination studies in humans.
Stimulants and norepinephrine-active drugs: Combined use adds cardiovascular stress — higher blood pressure, faster heart rate, and elevated body temperature from additive stimulation. inferred
Tramadol: Listed as potentially lethal in community databases. The proposed mechanism involves tramadol's combined serotonin/norepinephrine activity and weak opioid effects raising the risk of seizures and cardiovascular toxicity. No published case reports have been identified. safety citation needed
Opioids: The dominant fatality context. In Finnish post-mortem data, 69–92% of α-PVP-positive cases involved concurrent opioids, stimulants, or sedatives.[4] Mixed synthetic cathinone poisoning dramatically elevates toxicity.[26]
Alcohol: alcohol pre-exposure modifies α-PVP's reward and aversion balance in animal studies.[29] The direction and magnitude in humans remain uncharacterized.
Other synthetic cathinones: Combining α-PVP with MDPV produced significantly greater stimulant effects than either drug alone, particularly in females.[19]
Contraindications
8 knownCardiovascular disease: Heart conditions including arrhythmias, high blood pressure, coronary artery disease, and structural heart disease are absolute contraindications. α-PVP produces dose-dependent increases in heart rate and blood pressure,[30] and cardiovascular collapse is a component of fatal toxicity.[24]
Psychotic disorders and bipolar disorder: History of psychosis or bipolar disorder is an absolute contraindication given documented association with acute psychotic episodes and paranoid ideation.[27][8]
Seizure disorders: Seizures are a documented component of α-PVP toxicity,[24] representing a contraindication for those with epilepsy or lowered seizure threshold.
Kidney impairment: Muscle breakdown-induced kidney injury is a prominent feature of severe toxicity.[6][25] Pre-existing kidney disease increases vulnerability.
Pregnancy: No reproductive toxicity data exist for α-PVP. As a potent sympathomimetic, it poses theoretical risks to fetal development and placental blood flow. inferred
Harm Reduction[edit]
Forms & Identification
α-PVP is most commonly encountered as a white or off-white crystalline powder. Standard urine drug screens do not detect it — confirmation requires specialized laboratory testing. Visual appearance alone cannot confirm identity; substitution with other pyrrolidinophenones or cathinones is a known risk in unregulated supply.
Purity variation has direct implications for dosing. Start with the lowest possible amount and allow adequate time before considering redosing, particularly with oral administration where onset is slower and premature redosing is common.
Guidelines
- Test substance identity with reagent kits before use
- Pre-measure a single session's amount and store the remainder out of reach
- Avoid smoked or injected routes, which produce the most intense rush and strongest compulsive redosing urge
- Begin with threshold doses when encountering new material, regardless of prior experience
- Maintain hydration but avoid over-hydration — drink to thirst
- Eat a meal before use; stimulant appetite suppression makes eating difficult afterward
- Do not use alone — have a trusted person present who can recognize escalating paranoia or agitation
- Set a firm time limit; α-PVP sessions that extend beyond initial plans are the norm, not the exception
- Avoid sequential-day use; allow at minimum several days between sessions to reduce tolerance and neuroadaptive risk
Set & Setting
α-PVP's extreme dopamine selectivity makes set and setting less protective than with most psychoactives. At lower doses, a calm, familiar environment with trusted companions can reduce anxiety and paranoia. At higher doses or after repeated administrations, pharmacological compulsion overrides context — paranoia and psychosis can emerge regardless of surroundings.
Planning to use "just once" reliably fails with α-PVP. Pre-determining a total amount and removing access to remaining supply before a session begins is more effective than in-the-moment restraint.
Aftercare & integration. The comedown brings exhaustion, depressed mood, irritability, and intense cravings. Sleep recovery is the first priority — a dark, quiet room and patience are the primary tools.
Eat as soon as possible after stimulant effects subside. Calorie-dense, easy-to-digest food helps restore depleted energy. Hydrate steadily but not excessively. Expect mood and motivation to remain low for 24–72 hours — this is neurochemical rebound effect, not a permanent state.
If paranoia, hallucinations, or thought disorganization persist beyond 24 hours after last use, seek medical evaluation. Stimulant-induced psychosis typically resolves with cessation and sleep, but prolonged episodes require professional assessment.
Recovery & Support
α-PVP's extreme reinforcing potency means the transition from use to compulsive use happens faster than with most stimulants. Recognizing the pattern — sessions extending beyond planned limits, escalating doses, inability to discard remaining supply, using alone — is the critical first step.
No α-PVP-specific treatment protocols exist. Approaches developed for cocaine and methamphetamine dependence are generally applied, including cognitive behavioral therapy and contingency management. Medical evaluation is advisable for anyone with a history of regular use given documented risks of muscle damage, kidney injury, and brain inflammation.
Support resources include SAMHSA's National Helpline (1-800-662-4357), local addiction services, and peer support communities.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: The line between uncomfortable stimulation and medical emergency includes: chest pain or pressure, seizures, loss of consciousness, body temperature so high it can be felt through clothing, extreme confusion or delirium, aggressive behavior unresponsive to verbal calming, or inability to stop repetitive movements.
Immediate steps:
- 1. Call emergency services immediately if any of the above signs are present
- 2. Move the person to a cool, quiet environment
- 3. Remove objects that could cause injury during agitation
- 4. Do not physically restrain unless there is immediate danger to self or others — restraint can worsen elevated body temperature and muscle breakdown
- 5. If the person is unconscious and breathing, place them in the recovery position
- 6. Monitor breathing and temperature while waiting for help
What to tell the dispatcher: Name the substance (α-PVP, synthetic cathinone, or "Flakka"), approximate amount used, time of last dose, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
α-PVP is a controlled substance in most major jurisdictions, scheduled following the global synthetic cathinone regulation wave that began in 2011.[9]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Temporary Schedule I from February 2014; permanent placement effective March 1, 2017. Also covered under the Federal Analogue Act as a cathinone structural analog.[12] |
| European Union | Controlled (EU Council Decision) | EMCDDA risk assessment completed November 2015; Council Decision requiring all member states to implement control measures enacted June 27, 2016.[9] |
| United Kingdom | Psychoactive substance (PSA 2016) | Covered under Psychoactive Substances Act 2016, effective May 26, 2016. Sale, distribution, and supply for human use prohibited.[31] |
| Australia | Schedule 9 (Prohibited Substance) | TGA scheduling decision effective April 2018. Sale, manufacture, distribution, and use prohibited without research permit.[32] |
| Canada | Likely Schedule III (CDSA) | Cathinone is listed as Schedule III under the Controlled Drugs and Substances Act. α-PVP-specific listing was not confirmed.[33] citation needed |
| Japan | Designated substance | Regulated following reports of traffic accidents involving α-PVP-impaired drivers by 2014–2015.[15] |
Legal status changes frequently and varies by jurisdiction. This information reflects known status as of the article's last review and is not legal advice.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- rapid
- Tolerance reset
- 10 days
- Physical
- Low
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- cocaine · amphetamine · methamphetamine
Toxicity
Acute toxicity
No lethal dose has been established for α-PVP. The acute toxicity pattern follows the sympathomimetic toxidrome: rapid heart rate, high blood pressure, fast breathing, elevated body temperature, seizures, extreme agitation, muscle breakdown, and kidney injury.[26][27]
In 34 fatal cases in Finland (2018–2023), blood α-PVP concentrations ranged from 0.03 to 2.6 mg/L.[4] This wide range reflects extensive polydrug involvement rather than an intrinsic lethal threshold — only 1.7% of fatal synthetic cathinone cases involved α-PVP alone.[4] In 29% of α-PVP-positive deaths, the substance was implicated in the cause of death.[4]
α-PVP is not detected by standard urine drug screens. Confirmation requires specialized laboratory testing.[8][7] Emergency physicians should consider synthetic cathinone exposure in patients presenting with unexplained stimulant toxicity and negative routine screening.
Muscle breakdown
α-PVP causes muscle breakdown through two mechanisms. Indirect damage results from overstimulation — elevated body temperature, agitation, and sustained muscle hyperactivity. Direct muscle toxicity has been demonstrated in laboratory studies: α-PVP impairs mitochondrial function in muscle cells, depleting cellular energy and increasing oxidative stress.[6] This direct mechanism is distinct from and additive with sympathomimetic damage. Muscle breakdown-induced kidney injury is a prominent feature of severe toxicity.[28]
Cognitive toxicity
Repeated high-dose α-PVP administration impaired spatial learning and memory in rats through brain mitochondrial dysfunction.[20] Lower doses did not produce these effects, suggesting a dose threshold for cognitive damage that has not been characterized in humans.
Polydrug fatality context
In 118 post-mortem Finnish cases (2018–2023), α-PVP was present alongside opioids, stimulants, or sedatives in 69–92% of cases.[4] Mixed synthetic cathinone poisoning dramatically elevates toxicity risk compared to single-substance exposure.[29]
Psychological risks
α-PVP's extreme dopamine selectivity creates a pharmacological profile strongly associated with acute psychosis. Paranoia, psychotic episodes, hallucinations, aggression, and severe anxiety are documented in clinical case series.[30][8] Compounds with high dopamine selectivity carry the highest psychosis risk among synthetic cathinones.[30]
Behavioral toxicity extends to loss of behavioral control: erratic public behavior, aggression, and inability to safely operate vehicles were documented during the "Flakka" epidemic and in Japanese traffic accident reports.[8][15]
Chronic use produces neuroinflammation with sex-dependent patterns — males develop widespread brain inflammation, while females show predominantly peripheral inflammatory changes.[21]
Tolerance & dependence
α-PVP demonstrates among the highest reinforcing potency of any cathinone tested. In animal studies, 100% of rats acquired self-administration — an unusually high acquisition rate.[2] Reinforcing effectiveness correlates directly with dopamine selectivity, and α-PVP's extreme ratio predicts maximal compulsive-use liability.[2] Progressive ratio measures confirm reinforcing efficacy exceeding that of cocaine.[11]
Tolerance develops with repeated use through dopaminergic neuroadaptation. Studies of the closely related MDPV document lasting molecular changes persisting after withdrawal.[31] Specific tolerance parameters have not been characterized in published human studies. inferred
Cross-tolerance with other dopaminergic stimulants is expected based on shared mechanism but has not been studied for α-PVP specifically. inferred
Physical withdrawal has not been characterized in published human studies. Psychological dependence potential is strongly supported by preclinical data.
Drug Interactions
The interaction pharmacology of α-PVP is poorly characterized, with no substance-specific combination studies in humans.
Stimulant and monoamine-active compounds: α-PVP's potent norepinephrine reuptake inhibitor creates cardiovascular risk when combined with other stimulants or norepinephrine-active drugs. Co-administration with serotonergic agents such as MDMA carries risk of combined cardiovascular stress — severe high blood pressure, rapid heart rate, and dangerously elevated body temperature from additive stimulation. inferred
Tramadol: Listed as a potentially lethal combination in community databases. The proposed mechanism involves tramadol's combined serotonin/norepinephrine activity and weak opioid effects interacting with α-PVP's norepinephrine blockade, raising risks of seizures and cardiovascular toxicity. No published case reports documenting this combination have been identified. safety citation needed
Opioids: Polydrug use with opioids is the dominant context for α-PVP fatalities. In Finnish post-mortem data, 69–92% of α-PVP-positive cases involved concomitant opioids, stimulants, or sedatives.[4] Mixed synthetic cathinone poisoning confirms dramatically elevated toxicity.[29]
Alcohol: alcohol pre-exposure modifies α-PVP's reward and aversion balance in animal studies, altering both rewarding and aversive effects.[32] The direction and magnitude of human interaction remain uncharacterized.
Other synthetic cathinones: Co-administration of α-PVP with MDPV produced significantly greater stimulant effects than either drug alone, particularly in females.[22]
Contraindications
8 knownCardiovascular disease: Pre-existing heart conditions including arrhythmias, high blood pressure, coronary artery disease, and structural heart disease represent absolute contraindications. α-PVP produces dose-dependent increases in heart rate and blood pressure,[17] and cardiovascular collapse is a component of fatal toxicity.[27]
Psychotic disorders and bipolar disorder: History of psychosis or bipolar disorder is an absolute contraindication given α-PVP's documented association with acute psychotic episodes and paranoid ideation.[30][8]
Seizure disorders: Seizures are a documented component of α-PVP toxicity,[27] representing a contraindication for persons with epilepsy or lowered seizure threshold.
Kidney impairment: Muscle breakdown-induced kidney injury is a prominent feature of severe α-PVP toxicity.[6][28] Pre-existing kidney disease increases vulnerability.
Pregnancy: No reproductive toxicity data exist for α-PVP. As a potent sympathomimetic, it poses theoretical risks to fetal development and placental blood flow. inferred
Harm Reduction[edit]
Forms & Identification
α-PVP is most commonly encountered as a white or off-white crystalline powder. Because synthetic cathinones are not detected by standard urine drug screens and visual identification is unreliable, reagent testing provides the only accessible verification before specialized laboratory analysis. The substance's identity in unregulated supply cannot be confirmed by appearance alone — substitution with other pyrrolidinophenones or cathinones is a known risk.
Purity variation in unregulated supply has direct implications for dosing decisions. Start with the lowest possible amount and allow adequate time before considering redosing, particularly with oral administration where onset is slower and the temptation to redose prematurely is high.
Guidelines
- Test substance identity with reagent kits before use
- Pre-measure a single session's amount and store the remainder out of reach
- Avoid smoked or injected routes, which produce the most intense rush and strongest compulsive redosing urge
- Begin with threshold doses when encountering new material, regardless of prior experience
- Maintain hydration but avoid over-hydration — drink to thirst
- Eat a meal before use; stimulant appetite suppression makes eating difficult afterward
- Do not use alone — have a trusted person present who can recognize escalating paranoia or agitation
- Set a firm time limit; α-PVP sessions that extend beyond initial plans are the norm, not the exception
- Avoid sequential-day use; allow at minimum several days between sessions to reduce tolerance and neuroadaptive risk
Set & Setting
α-PVP's extreme dopamine selectivity makes set and setting unusually important — and unusually unreliable as protective factors. At lower doses, a calm, familiar environment with trusted companions can reduce anxiety and paranoia. At higher doses or after repeated administrations, pharmacological compulsion overrides contextual modulation: paranoia and psychosis can emerge regardless of environment.
The compulsive redosing pattern means that planning to use "just once" often fails. Pre-determining a total amount and removing access to remaining supply before a session begins is more effective than relying on in-the-moment judgment.
Aftercare & integration. The α-PVP comedown is characterized by exhaustion, depressed mood, irritability, and intense cravings. Sleep recovery is the first priority — a dark, quiet room and patience are the primary tools.
Eat as soon as possible after the stimulant effects subside. Calorie-dense, easy-to-digest food helps restore depleted energy. Hydrate steadily but not excessively. Expect mood and motivation to remain low for 24–72 hours; this is neurochemical rebound effect, not a permanent state.
If psychotic symptoms — paranoia, hallucinations, thought disorganization — persist beyond 24 hours after last use, seek medical evaluation. Stimulant-induced psychosis typically resolves with cessation and sleep, but prolonged episodes require professional assessment.
Recovery & Support
α-PVP's extreme reinforcing potency makes the transition from use to compulsive use faster than with most stimulants. Recognizing the pattern — sessions extending beyond planned limits, escalating doses, inability to discard remaining supply, using alone — is the critical first step.
No α-PVP-specific treatment protocols exist. Treatment approaches developed for cocaine and methamphetamine dependence are generally applied, including cognitive behavioral therapy and contingency management. Medical evaluation is advisable for anyone with a history of regular use, given the documented risks of muscle damage, kidney injury, and neuroinflammation.
Support resources include SAMHSA's National Helpline (1-800-662-4357), local addiction services, and peer support communities.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: The line between uncomfortable stimulation and medical emergency includes: chest pain or pressure, seizures, loss of consciousness, body temperature so high it can be felt through clothing, extreme confusion or delirium, aggressive behavior unresponsive to verbal calming, or inability to stop repetitive movements.
Immediate steps:
- 1. Call emergency services immediately if any of the above signs are present
- 2. Move the person to a cool, quiet environment
- 3. Remove objects that could cause injury during agitation
- 4. Do not physically restrain unless there is immediate danger to self or others — restraint can worsen elevated body temperature and muscle breakdown
- 5. If the person is unconscious and breathing, place them in the recovery position
- 6. Monitor breathing and temperature while waiting for help
What to tell the dispatcher: Name the substance (α-PVP, synthetic cathinone, or "Flakka"), approximate amount used, time of last dose, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
α-PVP is a controlled substance in most major jurisdictions, scheduled following the global wave of synthetic cathinone regulation that began in 2011. Permanent scheduling was driven by mounting evidence of abuse potential, public health incidents during the 2014–2015 "Flakka" epidemic, and the EMCDDA risk assessment completed in November 2015.[9]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Temporary Schedule I from February 2014; permanent placement effective March 1, 2017. Also covered under the Federal Analogue Act as a cathinone structural analog.[12] |
| European Union | Controlled (EU Council Decision) | EMCDDA risk assessment completed November 2015; Council Decision requiring all member states to implement control measures enacted June 27, 2016.[9] |
| United Kingdom | Psychoactive substance (PSA 2016) | Covered under Psychoactive Substances Act 2016, effective May 26, 2016. Sale, distribution, and supply for human use prohibited.[33] |
| Australia | Schedule 9 (Prohibited Substance) | TGA scheduling decision effective April 2018. Sale, manufacture, distribution, and use prohibited without research permit.[34] |
| Canada | Likely Schedule III (CDSA) | Cathinone is listed as Schedule III under the Controlled Drugs and Substances Act. α-PVP-specific listing was not confirmed.[35] citation needed |
| Japan | Designated substance | Regulated following reports of traffic accidents involving α-PVP-impaired drivers by 2014–2015.[15] |
Frequently asked questions
What is A-PVP?
A-PVP is a synthetic cathinone stimulant of the pyrrolidinophenone subclass, known by the street name Flakka. It acts as a pure dopamine and norepinephrine reuptake inhibitor with a DAT/SERT selectivity ratio exceeding 4,030, first detected on European drug markets in 2011.
How long does A-PVP last?
Total duration by route of administration — Smoked: 20 – 60 min; Insufflated: 2 – 5 hours; Oral: 2 – 6 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for A-PVP?
Psychedex publishes a dosage table for A-PVP on this page covering these routes of administration: insufflated, smoked, oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with A-PVP?
The highest-severity documented interactions for A-PVP: Ibogaine (Lethal), Alpha-2 adrenergic receptor antagonist (Dangerous), Amphetamines (Dangerous), Anticholinergics (Dangerous), Antipsychotics (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is A-PVP addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for A-PVP: tolerance builds rapid; full reset takes 10 days; cross-tolerance develops with cocaine, amphetamine, methamphetamine, MDPV, methylphenidate. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1] ^abcPersson M, Vikingsson S, Kronstrand R, Green H (2024) Characterization of neurotransmitter inhibition for seven cathinones by a proprietary fluorescent dye method. — Drug Testing and Analysis doi:10.1002/dta.3547
- [2]
- [3] ^abcNguyen VT, Harris AC, Eltit JM (2024) Structural and functional perspectives on interactions between synthetic cathinones and monoamine transporters. — Advances in Pharmacology doi:10.1016/bs.apha.2023.09.001
- [4]
- [5] ^abcdKolanos R, Sakloth F, Jain AD, Partilla JS, Baumann MH, Glennon RA (2015) Structural Modification of the Designer Stimulant α-Pyrrolidinovalerophenone (α-PVP) Influences Potency at Dopamine Transporters. — ACS Chemical Neuroscience doi:10.1021/acschemneuro.5b00160
- [6] ^abcZhou X, Luethi D, Sanvee GM, Bouitbir J, Liechti ME, Krähenbuhl S (2019) Molecular Toxicological Mechanisms of Synthetic Cathinones on C2C12 Myoblasts. — International Journal of Molecular Sciences doi:10.3390/ijms20071561
references
- [1] ^abcPersson M, Vikingsson S, Kronstrand R, Green H (2024) Characterization of neurotransmitter inhibition for seven cathinones by a proprietary fluorescent dye method. — Drug Testing and Analysis doi:10.1002/dta.3547
- [2] ^abcdefghGannon BM, Baumann MH, Walther D, Jimenez-Morigosa C, Sulima A, Rice KC, Collins GT (2018) The abuse-related effects of pyrrolidine-containing cathinones are related to their potency and selectivity to inhibit the dopamine transporter. — Neuropsychopharmacology doi:10.1038/s41386-018-0209-3
- [3] ^abcdNguyen VT, Harris AC, Eltit JM (2024) Structural and functional perspectives on interactions between synthetic cathinones and monoamine transporters. — Advances in Pharmacology doi:10.1016/bs.apha.2023.09.001
- [4]
- [5]
- [6] ^abcZhou X, Luethi D, Sanvee GM, Bouitbir J, Liechti ME, Krähenbuhl S (2019) Molecular Toxicological Mechanisms of Synthetic Cathinones on C2C12 Myoblasts. — International Journal of Molecular Sciences doi:10.3390/ijms20071561